

1 **A phase I/II clinical trial of intradermal, controllable self-replicating RNA vaccine**

2 **EXG-5003 against SARS-CoV-2**

3

4 Takenao Koseki,<sup>1</sup> Mayumi Teramachi,<sup>2</sup> Minako Koga<sup>3</sup>, Minoru S.H. Ko<sup>4</sup>, Tomokazu Amano<sup>4</sup>,  
5 Hong Yu<sup>4</sup>, Misa Amano<sup>4</sup>, Erica Leyder<sup>4</sup>, Maria Badiola<sup>4</sup>, Priyanka Ray<sup>4</sup>, Jiyoung Kim<sup>4</sup>, Akihiro  
6 C. Ko<sup>4</sup>, Achouak Achour<sup>5</sup>, Nan-ping Weng<sup>5</sup>, Takumi Imai<sup>6</sup>, Hisako Yoshida<sup>6</sup>, Satsuki Taniuchi<sup>6</sup>,  
7 Ayumi Shintani<sup>6</sup>, Hidetsugu Fujigaki<sup>7</sup>, Masashi Kondo<sup>2,8</sup>, Yohei Doi<sup>9,10,11</sup>

8

9 1 Department of C Pharmacotherapeutics and Informatics, Fujita Health University School of  
10 Medicine, Toyoake, Aichi, Japan

11 2 Center for Clinical Trial and Research Support, Fujita Health University School of Medicine,  
12 Toyoake, Aichi, Japan

13 3 KM Pharmaceutical Consulting, Washington, D.C., USA

14 4 Elixirgen Therapeutics, Inc., Baltimore, MD, USA

15 5 Laboratory of Molecular Biology and Immunology, National Institute on Aging, National  
16 Institutes of Health, Baltimore, MD, USA

17 6 Department of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan  
18 University, Osaka, Japan

19 7 Department of Advanced Diagnostic System Development, Fujita Health University Graduate  
20 School of Health Sciences, Toyoake, Aichi, Japan

21 8 Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake,  
22 Aichi, Japan

23 9 Departments of Microbiology and Infectious Diseases, Fujita Health University School of  
24 Medicine, Toyoake, Aichi, Japan

25 10 Center for Infectious Disease Research, Fujita Health University, Toyoake, Aichi, Japan

26 11 Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh,  
27 Pennsylvania, USA

28

29 **Running head:** Phase I/II trial of SARS-CoV-2 srRNA vaccine EXG-5003

30

31 **Keywords:** COVID-19, messenger RNA, receptor-binding domain, safety, immunogenicity

32

33 **Correspondence:**

34 Yohei Doi, MD, PhD, Departments of Microbiology and Infectious Diseases, Fujita Health

35 University School of Medicine, Toyoake, Aichi 470-1192 Japan. Phone: +81-562-93-2433, Fax:

36 +81-562-93-4003, Email: yoheidoi@fujita-hu.ac.jp.

37

38

39 **Abstract**

40 mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have  
41 played a key role in reducing morbidity and mortality from coronavirus disease 2019  
42 (COVID-19). We conducted a double-blind, placebo-controlled phase I/II trial to evaluate the  
43 safety, tolerability, and immunogenicity of EXG-5003, a two-dose, controllable self-replicating  
44 RNA vaccine against SARS-CoV-2. EXG-5003 encodes the receptor binding domain (RBD) of  
45 SARS-CoV-2 and was administered intradermally without lipid nanoparticles (LNP). The  
46 participants were followed for 12 months. Forty healthy participants were enrolled in Cohort 1 (5  
47 µg per dose, n = 16; placebo, n = 4) and Cohort 2 (25 µg per dose, n = 16; placebo, n = 4). No  
48 safety concerns were observed with EXG-5003 administration. SARS-CoV-2 RBD antibody  
49 titers and neutralizing antibody titers were not elevated in either cohort. Elicitation of antigen-  
50 specific cellular immunity was observed in the EXG-5003 recipients in Cohort 2. At the 12-  
51 month follow-up, participants who had received an approved mRNA vaccine (BNT162b2 or  
52 mRNA-1273) >1 month after receiving the second dose of EXG-5003 showed higher cellular  
53 responses compared to equivalently vaccinated participants in the placebo group. The findings  
54 suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-  
55 CoV-2 mRNA vaccines.

56

57

## 58 **Introduction**

59 Since its onset in late 2019, the COVID-19 pandemic has resulted in over 7 million deaths <sup>1</sup> and  
60 has left many more people with negative long-term health consequences worldwide. Against this  
61 backdrop, the rapid development of multiple COVID-19 vaccines has been a significant  
62 achievement in the field of biomedical research, with billions of vaccine doses distributed and  
63 administered worldwide <sup>2</sup>. In particular, synthetic mRNA vaccines made a noteworthy debut  
64 following extensive fundamental and preclinical investigations that preceded the pandemic <sup>3,4</sup>.  
65 With their rapid development, cell-free manufacturing, and excellent clinical efficacy, mRNA  
66 vaccines surpassed conventional live-attenuated, inactivated, and protein-based subunit vaccines  
67 in the race for early vaccine approval. Nonetheless, mass administration of mRNA vaccines has  
68 also revealed challenges, including adverse effects and the need for multiple booster doses.  
69 Another consideration in vaccine development is the role of vaccine-induced cellular immunity  
70 in protection against severe disease, hospitalization, and death. As SARS-CoV-2 variants that  
71 evade neutralizing antibodies continue to emerge, the significance of cellular immunity,  
72 especially CD8<sup>+</sup> T cells, in safeguarding against severe disease in the long run is increasingly  
73 appreciated <sup>5-7</sup>. In contrast to the limited cross-reactivity of neutralizing antibodies induced by  
74 vaccines against variants, T cell responses elicited by vaccines demonstrate excellent cross-  
75 reactivity. However, the approved mRNA vaccines induce weak cellular immunity, especially in  
76 CD8<sup>+</sup> T cells <sup>8-10</sup>, that wanes rapidly along with humoral immunity <sup>11,12</sup>, though some groups  
77 report longer-lasting T cell immunity <sup>13-15</sup>.  
78 The weak induction and rapid waning of cellular immunity of the currently approved mRNA  
79 vaccines could be overcome by another type of mRNA vaccines using self-replicating RNA  
80 (srRNA), also called self-amplifying RNA (saRNA or SAM-RNA) <sup>16</sup>, as it is known to be a

81 strong inducer of cellular immunity in animal studies <sup>17-23</sup>. However, clinical trials of the SARS-  
82 CoV-2 vaccine based on the srRNA/saRNA platform thus far have shown lower than expected  
83 immunogenicity in humans <sup>24-26</sup>.

84 The EXG-5003 vaccine is based on srRNA/saRNA technology, but it is engineered to be  
85 controllable by temperature: it functions at around 33°C – skin temperature, but does not  
86 function at 37°C – core body temperature <sup>27</sup>. Thus, this novel RNA vaccine platform is called  
87 controllable self-replicating RNA (c-srRNA) <sup>27</sup>. Unlike mRNA and srRNA/saRNA vaccines that  
88 are administered to skeletal muscles, the c-srRNA vaccine platform is optimized for intradermal  
89 delivery, which may enhance cellular immunity as it is well known that intradermal vaccination  
90 can induce strong cellular immunity <sup>28,29</sup>. Also, unlike mRNA and srRNA/saRNA vaccines that  
91 are complexed with LNP, the c-srRNA vaccine platform is not complexed with LNP and is  
92 delivered as naked RNA, which may reduce local reactogenicity in the skin, which has often  
93 been an issue for previous intradermal vaccines. Preclinical studies have shown that intradermal  
94 vaccination with EXG-5003 alone induced robust cellular immunity but did not induce humoral  
95 immunity <sup>27</sup>. However, EXG-5003 showed priming effects, as demonstrated by a rapid and  
96 strong induction of humoral immunity after subsequent exposure to the same or variant RBD  
97 antigen compared with control <sup>27</sup>.

98 Here, we report the results of a phase 1/2 study to evaluate the safety, tolerability, and  
99 immunogenicity of EXG-5003 in healthy adults.

100

## 101 **Results**

### 102 **Participants**

103 Of 46 participants who gave consent, 40 participants met the inclusion criteria. They were  
104 enrolled in Cohort 1 and Cohort 2 of this study, with 16 participants assigned to receive  
105 EXG-5003 and 4 participants to receive placebo in each cohort, respectively (Figure 1).  
106 In Cohort 1, one participant in the EXG-5003 5 µg group did not receive the second dose due to  
107 an unrelated injury requiring hospitalization. All 40 participants completed follow-up to Day 57.  
108 One and 3 participants in Cohort 1 (EXG-5003 5 µg group) and Cohort 2 (EXG-5003 25 µg  
109 group) did not return at the 1-year final follow-up, respectively.  
110 The participant backgrounds for the full analysis set (FAS) in this study are shown in Table 1.  
111 For Cohort 1, males accounted for 10/16 (62.5%) in the EXG-5003 5 µg group and 3/4 (75%) in  
112 the placebo group. The median age was 39.5 years in the EXG-5003 5 µg group and 48 years in  
113 the placebo group. For Cohort 2, males accounted for 7/16 (43.8%) in the EXG-5003 25 µg  
114 group and 4/4 (100%). The median age was 43 years in the EXG-5003 25 µg group and 44 years  
115 in the placebo group.

## 116 **Safety**

117 Local adverse events or reactogenicity associated with the administration of EXG-5003 are  
118 summarized in Figure 2A. Only Grade 1 events were reported from a small number of  
119 participants. A photo shows an example of observed redness (Figure 2A). Systemic adverse  
120 events are summarized in Figure 2B. Only minor events, mostly Grade 1 and some Grade 2,  
121 were reported. It is noteworthy that the reactogenicity and systemic adverse events associated  
122 with EXG-5003 were much lower than the approved mRNA vaccines<sup>3,4</sup> and other  
123 srRNA/saRNA vaccines<sup>26,30</sup>. This low reactogenicity of the intradermal EXG-5003 vaccine was  
124 expected because the vaccine contains only RNA and did not contain skin irritants such as lipids  
125 or oils.

126 **Short-term humoral immunity elicited by EXG-5003**

127 The results of the FAS for anti-SARS-CoV-2 RBD antibody titers are shown in Figure 3, which  
128 plots the geometric means of titer for each participant by dose group and by time of evaluation  
129 over time (Table S1). Placebo groups consisting of 4 participants each from Cohort 1 and Cohort  
130 2 were plotted together. As external controls, serum from four convalescent individuals who  
131 were hospitalized for COVID-19 and one serum sample from the WHO COVID-19 reference  
132 were analyzed in parallel (Table S2). Because the participants were allowed to receive licensed  
133 COVID-19 vaccines after Day 57, humoral immunity elicited by EXG-5003 alone could be  
134 assessed until Day 57. As shown in Figure 3, some individuals in the placebo group showed  
135 antibody titers higher than those who were vaccinated at some time points. They were negative  
136 for COVID-19 based on ELISA results against the nucleoprotein of SARS-CoV-2 and did not  
137 receive licensed COVID-19 vaccines during this period; thus, the reason for these high titers was  
138 not clear. For EXG-5003 vaccinated groups, low or undetectable levels of an anti-SARS-CoV-2  
139 RBD antibody were observed (Figure 3A). Similarly, the results of the FAS for neutralizing  
140 antibody (ntAb), by both cell-free SARS-CoV-2 neutralization assay (Figure 3B, Table S3) and  
141 pseudotyped lentivirus assay (Figure 3C, Table S4), showed low or no increase of titers  
142 compared to the placebo group. Data points shown in red indicate individuals who received at  
143 least one dose of the approved mRNA vaccines (BNT162b2 or mRNA-1273) at the time of  
144 serum collection. These data will be discussed later.

145 **Short-term cellular immunity elicited by EXG-5003**

146 The results of the FluoroSpot assay for IFN- $\gamma$  and IL-4 are shown in Figure 4. Cellular immunity  
147 was tested by stimulating PBMCs with a 15-mer peptide pool and a 9-mer peptide pool, which  
148 cover the RBD antigen. Short-term cellular immunity (up to Day 57) did not seem to be induced

149 by EXG-5003 compared to the placebo and external controls, including convalescent individuals  
150 and individuals vaccinated with the BNT162b2 mRNA vaccine (Figure 4). However, some  
151 individuals in the placebo group and one individual in the external controls before BNT162b2  
152 vaccination (BNT16b2 [pre]) showed cellular immunity comparable to the convalescent  
153 individuals. Also, two of three individuals who received one dose of BNT162b2 vaccine  
154 (BNT162b2 [1 dose]) and one of three individuals who received two doses of BNT162b2  
155 vaccine (BNT162b2 [2 doses]) showed rather low cellular immunity, which is comparable to the  
156 EXG-5003 vaccinated group. Measurements for Cohort 1 (16 EXG-5003 5 µg and 4 placebo  
157 participants) and Cohort 2 (16 EXG-5003 25 µg and 4 placebo participants) were conducted in  
158 different batches on separate periods. We reasoned that the assays performed at the same time  
159 would demonstrate more consistent results. Therefore, we looked at Cohort 2 separately (Figure  
160 5). This showed a clearer pattern of gradual increase of cellular immunity in the EXG-5003  
161 group compared to the placebo group (Figure 5). Notably, some individuals who received  
162 EXG-5003 25 µg even after a single dose showed higher cellular immunity than two of three  
163 individuals who received a single dose of BNT162b2 vaccine (BNT162b2 [1 dose]) and one of  
164 three individuals who received two doses of BNT162b2 vaccine (BNT162b2 [2 doses]).

165 **Long-term humoral immunity elicited by EXG-5003 following administration of licensed**  
166 **vaccines**

167 During this trial, approved SARS-CoV-2 vaccines became available in Japan. Therefore, the  
168 participants were unblinded from randomization at Day 57 and allowed to receive the approved  
169 SARS-CoV-2 vaccines (BNT162b2, mRNA-1273, ChAdOx1, NVX-CoV2373) during the rest of  
170 the follow-up period. Some participants started to receive the approved vaccines. At the time of  
171 the final 1-year follow-up, some participants took two or three doses of the approved vaccines



172 (BNT162b2 or mRNA-1273), whereas some participants did not take any approved vaccines.

173 Whether the participants took the approved vaccines or not rests on the participants' free-will.

174 Although the number of participants in these subgroups was very small, we expected that the

175 general trends without inference could be observed.

176 Although the data were not necessarily consistent among the assays (Ab titer, ntAb titer

177 [pseudovirus], ntAb titer [cell-free]), there were general tendencies that participants who

178 received EXG-5003 vaccines (both 5  $\mu$ g and 25  $\mu$ g groups) showed higher antibody levels than

179 participants who did not receive EXG-5003 (placebo group; PBO) (Figure 6). The timing of

180 blood sampling after the dosing of approved vaccines was not controlled, but there was no clear

181 pattern of timing differences among the three groups, i.e., PBO, EXG-5003 (5  $\mu$ g), EXG-5003

182 (25  $\mu$ g).

183 Notably, at 3 months post EXG-5003 vaccination when participants received only a single dose

184 of BNT162b2 or mRNA-1273, participants who received prior EXG-5003 showed Ab titers

185 higher than participants who did not receive EXG-5003 (PBO) (Figure 6A). Especially, EXG-

186 5003 25  $\mu$ g group showed the Ab titer comparable to participants who received two doses of

187 BNT162b2 or mRNA-1273, but not received EXG-5003 (PBO) (Figure 6A). Similar trends were

188 observed for ntAb titers assessed by both cell-free assay (Figure 6B) and pseudovirus assay

189 (Figure 6C).

190 Taken together, EXG-5003 may have a priming effect for humoral immunity on subsequent

191 heterologous vaccine administration.

192 **Long-term cellular immunity elicited by EXG-5003 following administration of licensed**

193 **vaccines**

194 The priming effect of EXG-5003 on subsequent heterologous vaccine administration was more  
195 clearly seen for cellular immunity. Figure 7A shows cellular immunity assayed by 15-mer  
196 peptide stimulation (i.e., CD4+, CD8+ T cells) at the 1-year follow-up (Table S5). Among  
197 participants who did not receive any approved vaccines by the 1-year follow-up, some  
198 individuals who received EXG-5003 vaccines possessed higher cellular immunity compared to  
199 the placebo group. These individuals were negative for SARS-CoV-2 nucleoprotein and, thus,  
200 were not infected throughout the study period. This trend was observed for participants who  
201 received two or three doses of an approved vaccine. The timing of blood sampling after the last  
202 vaccination (either EXG-5003 or approved vaccines) was around 10 months for no approved  
203 vaccine group, around 8 months for two doses of approved vaccines group, and around 1 month  
204 for three doses of the approved vaccines group (see the details in Figure 7 legend). The external  
205 controls were reproduced from Figure 5 for the comparison. For the convalescent group, blood  
206 sampling was done 20, 21, 21, and 22 days from the onset of COVID-19 symptoms. Blood  
207 sampling of BNT162b2 vaccine groups occurred before vaccination (BNT162b2 [pre]), 2 weeks  
208 after the first vaccination (BNT162b2 [1 dose]), and 2 weeks after the second vaccination  
209 (BNT162b2 [2 doses]) (Table S6). Two weeks after the vaccination is considered the time for  
210 peak cellular immunity<sup>11,12,25,26</sup>.

211 Figure 7B shows cellular immunity assayed by 9-mer peptide stimulation (i.e., mainly CD8+ T  
212 cells) at the 1-year follow-up. There were fewer 9-mer than 15-mer peptide results as we  
213 prioritized the 15-mer peptide assays when blood samples were insufficient to run both.  
214 However, the priming effect of EXG-5003 was even more clearly seen compared to 15-mer  
215 peptide results (Figure 7A). Interestingly, both convalescent and twice BNT162b2 vaccinated  
216 individuals (BNT162b2 [2 doses]) in the control group showed very low 9-mer peptide results.

217 This may be consistent with the notion that mRNA vaccine is a weak inducer of CD8<sup>+</sup> T cells<sup>8-</sup>  
218 <sup>10</sup>. The result shown in Figure 7B further highlights the potential of the EXG-5003 vaccine to  
219 enhance the CD8<sup>+</sup> T cell response.

220

## 221 **Discussion**

222 Synthetic mRNA vaccines have been enormously successful in combating the SARS-CoV-2  
223 pandemic. However, it has also become clear that humoral immunity, and subsequently cellular  
224 immunity, rapidly wane, and thus, repeated vaccinations are recommended<sup>11,12</sup>. Ideally, a  
225 vaccine that can provide long-term immune protection is desirable. Also, a vaccine that can  
226 provide not only humoral immunity, but strong cellular immunity, is desirable, because the  
227 cellular immunity is known to be more protective against variant forms of the virus. We  
228 attempted to address these issues with a novel intradermal c-srRNA vaccine platform, which is  
229 different from all currently licensed SARS-CoV-2 vaccines or those under development. For  
230 example, as far as we know, EXG-5003 is the only RNA vaccine that is administered  
231 intradermally and without LNP. Most likely due to this feature, the vaccine showed an excellent  
232 safety profile, including very few local and systemic adverse events.

233 As a standalone vaccine, the EXG-5003 vaccine did not induce Ab production. To some extent,  
234 this was expected from mouse studies<sup>27</sup>. On the other hand, mouse studies showed the induction  
235 of strong cellular immunity in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells<sup>27</sup>, but the cellular immunity in  
236 humans was rather weak with a dose of up to 25 µg. However, it is worth noting that the level of  
237 cellular immunity achieved by EXG-5003 was comparable to traditional srRNA/saRNA  
238 vaccines, which are administered intramuscularly with LNP<sup>25,26</sup>. Although the dose of traditional  
239 srRNA/saRNA vaccines was limited to 10 µg due to local and systemic adverse events, including

240 grade 3 severity<sup>26</sup>, EXG-5003 can be dosed up to 25 µg without any severe adverse events. In  
241 fact, the clinical trial originally considered dose escalation of up to 100 µg, but this was not  
242 conducted due to insufficient induction of Ab production at 5 and 25 µg doses. Therefore, it  
243 remains to be seen whether higher doses of EXG-5003 can induce more robust cellular immunity  
244 as well as humoral immunity.

245 Surprisingly, EXG-5003 appears to provide long-term and enhanced priming effects on  
246 heterologous synthetic mRNA vaccines. For example, for T cell responses, assessed by  
247 FluoroSpot assays, in individuals who received EXG-5003 showed higher T cell immunity even  
248 around 10 months after receiving the licensed mRNA vaccines (i.e., booster) compared to  
249 individuals who did not receive EXG-5003. This priming effect was more pronounced in the  
250 FluoroSpot assays using a 9-mer peptide pool than those using a 15-mer peptide pool. Assuming  
251 that the former represents mainly CD8<sup>+</sup> T cells and the latter represents CD4<sup>+</sup> and CD8<sup>+</sup> T  
252 cells<sup>31</sup>, the result is consistent with the preferential induction of MHC-I-mediated CD8<sup>+</sup> T cells  
253 in mouse studies<sup>27</sup>. Furthermore, the priming effect of EXG-5003 was also consistent with the  
254 priming effect shown in mouse studies<sup>27</sup>. These results suggest that giving EXG-5003 as a  
255 primer vaccine provides immunological benefits to subsequent booster synthetic mRNA  
256 vaccines. As we showed in our mouse model, EXG-5003 induces the same immune  
257 enhancement effects even when used as a booster vaccine. Therefore, it is conceivable that a  
258 booster dose of EXG-5003 may confer immunologic benefits to people who have already  
259 received licensed mRNA vaccines. For such purposes, another vaccine, EXG-5008 — the same  
260 c-srRNA platform encoding for both RBD and nucleoproteins derived from SARS-CoV-2 and  
261 MERS-CoV<sup>27</sup>, may be more suitable because it also has the benefit of more conserved  
262 nucleoproteins as antigens and intent to be a so-called pan-coronavirus vaccine.

263 One potential advantage of using the combination of c-srRNA vaccine and synthetic mRNA  
264 vaccine as heterologous prime-boost vaccines is that both are RNAs; thus, the advantages of  
265 RNA vaccines, such as rapid development and simple manufacturing, apply to both.  
266 Furthermore, the c-srRNA vaccine does not use LNPs or nucleoside modifications, which are  
267 additional attractive features.

268 We acknowledge the limitations of our study. As a first-in-human trial of a novel c-srRNA  
269 vaccine platform, the number of participants was designed to be small. Furthermore, participants  
270 were allowed to take subsequent booster vaccines at their own will, resulting in even smaller  
271 numbers of participants in each subgroup of heterologous prime-boost vaccinations. Because of  
272 these small numbers, only the trends, without statistical inferences, were obtained.

273 In summary, we conducted a double-blind, placebo-controlled phase I/II trial to evaluate the  
274 safety, tolerability, and immunogenicity of EXG-5003, a two-dose, controllable self-replicating  
275 RNA vaccine against SARS-CoV-2. No safety concerns were observed with EXG-5003  
276 administration. SARS-CoV-2 RBD antibody titers and neutralizing antibody titers were not  
277 elevated in either cohort, but elicitation of antigen-specific cellular immunity was observed in the  
278 EXG-5003 recipients in Cohort 2. Additionally, those who received an approved mRNA vaccine  
279 after receiving EXG-5003 showed higher cellular responses compared to equivalently vaccinated  
280 participants in the placebo group, suggesting a priming effect towards the cellular immunity of  
281 approved SARS-CoV-2 mRNA vaccines, and the potential applications of c-srRNA based  
282 vaccines against pathogens that depend on the cellular immunity protection.

283

## 284 **Materials and Methods**

### 285 **EXG-5003 vaccine**

286 The EXG-5003 vaccine was developed by Elixirgen Therapeutics, Inc. Its design and preclinical  
287 studies are described in the previous paper<sup>27</sup>. In brief, this RNA vaccine platform is based on a  
288 self-replicating RNA (srRNA), also called self-amplifying RNA (saRNA or SAM), derived from  
289 the Venezuelan Equine Encephalitis virus. This RNA vaccine platform contains temperature-  
290 sensitive mutations, which makes it function at around 33°C (skin temperature) but not at around  
291 37°C (core body temperature). Thus, it is called controllable self-replicating RNA (c-srRNA).  
292 The vaccine encodes the RBD of SARS-CoV-2 spike protein as an antigen. The EXG-5003 is  
293 intradermally delivered as naked RNA, i.e., without lipid nanoparticles. The EXG-5003 c-srRNA  
294 was diluted by Lactated Ringer's solution at the clinical site and adjusted to the desired  
295 concentration.

#### 296 **Trial design and participants**

297 This was a single-center, phase 1/2, randomized, double-blinded, placebo-controlled trial  
298 conducted to evaluate the safety, tolerability, and immunogenicity of EXG-5003 in adults. The  
299 protocol, amendments, and overall oversight were approved by the Institutional Review Board  
300 for the Fujita Health University Hospitals (F-D-18) (jRCT2041210013, NCT04863131). The  
301 study was conducted in accordance with the Declaration of Helsinki.  
302 The participants provided written informed consent before enrollment and randomization.  
303 Healthy adults aged 20 to 55 years who had a negative PCR test for SARS-CoV-2 and a negative  
304 anti-SARS-CoV-2 spike protein antibody were eligible. Key exclusion criteria included previous  
305 receipt of approved SARS-CoV-2 vaccine, symptoms consistent with COVID-19, uncontrolled  
306 cardiovascular, hematologic, respiratory, gastrointestinal, renal, and neuropsychiatric diseases,  
307 diabetes, autoimmune diseases, history of hepatitis B, hepatitis C, HIV infection, anaphylaxis or

308 seizure, previous receipt of any SARS-CoV-2 vaccine, and ongoing pregnancy. Women of  
309 childbearing age were required to document a negative pregnancy test.

### 310 **Study procedures**

311 The study enrolled two sequential cohorts, each consisting of 20 participants. Cohort 1  
312 participants received 5 µg of EXG-5003 or placebo, whereas Cohort 2 participants received 25  
313 µg of EXG-5003 or placebo. Participants were randomized in a 4:1 ratio to receive two 0.1 mL  
314 intradermal injections of either EXG-5003 or placebo (Lactated Ringer's solution) to the  
315 posterior upper arm region, 28 days apart on Day 1 and Day 29 of randomization. Allocation of  
316 participants to the study arms were performed via a web-based interactive system by unblinded  
317 allocation staff, followed by preparation of EXG-5003 or placebo solution by unblinded  
318 pharmacists. The unblinded allocation staff and pharmacists who managed the study vaccine  
319 preparation had no role in participant assessment. The participants were followed for 52 weeks.  
320 The participants were allowed to receive SARS-CoV-2 vaccines that were approved in Japan  
321 (BNT162b2, mRNA-1273, ChAdOx1, NVX-CoV2373) after Day 57 during the follow-up  
322 period. In retrospect, most participants of this study received either BNT162b2 or mRNA-1273.  
323 For humoral immunity comparison, the following sera were used: one WHO standard serum;  
324 four convalescent individuals (serum was collected from COVID-19 patients hospitalized at  
325 Fujita Health University Hospital at 20, 21, 21, and 22 days after the onset of symptoms,  
326 respectively).  
327 For cellular immunity comparison, blood samples were used from: three convalescent  
328 individuals (blood was collected from COVID-19 patients hospitalized at Fujita Health  
329 University Hospital at 20, 21, and 22 days after the onset of symptoms, respectively [patients are  
330 the same convalescent individuals described above]); four individuals (unrelated to this clinical

331 trial) before receiving a 1st dose [BNT162b2 (pre)]; three individuals two weeks after receiving  
332 the BNT162b2 mRNA vaccine [BNT162b2 (1 dose)]; and three individuals two weeks after  
333 receiving the 2nd dose [BNT162b2 (2 doses)].

#### 334 **Humoral immunity assays**

##### 335 **Anti-RBD antibody**

336 Antibody titers against SARS-CoV-2, including any antibodies that bind to the RBD, were  
337 measured by electrochemiluminescent (ECL) technology. The ECL is an immunoassay based on  
338 the excitation of a ruthenium sulfo-tagged antibody by an electrical current. Biotinylated RBD of  
339 the spike protein from SARS-CoV-2 (2019-nCoV) was captured onto an MSD Gold Streptavidin  
340 coated plate (ECL capable) for coating. This recombinant protein consisted of 234 amino acids  
341 corresponding to the RBD and had a predicted molecular mass of 28.7 kDa. A blocker solution  
342 was added to the wells and subsequently washed. The antibodies against the SARS-CoV-2 spike  
343 protein in the samples were captured onto the coated plate. After thorough washing of the wells  
344 to remove the unbound antibodies, sulfo-tagged anti-human IgG-FC was added to the wells to  
345 form a complex with the antibodies against the RBD. The excess unbound conjugate was then  
346 removed by further washing. The reaction was then developed by adding MSD read buffer, and  
347 the assay plate was read using an MSD ECL plate reader. The electrochemiluminescence signal  
348 generated was relative to the amount of antibodies against the RBD present in the samples tested.

##### 349 **Cell-free SARS-CoV-2 neutralization assay**

350 Neutralizing antibody titers against the RBD of SARS-CoV-2 were measured by AlphaLISA  
351 technology. The AlphaLISA is an amplified luminescent proximity homogenous immunoassay  
352 based on the proximity of two types of beads: acceptor and donor beads. Briefly, all samples  
353 were initially diluted in assay diluent, diluted in MRD diluent, and transferred to an assay plate.



354 They were then incubated with a mixture of acceptor beads (streptavidin-coated) and  
355 recombinant spike-RBD protein (biotinylated). During this step, the neutralizing antibodies  
356 bound to the spike-RBD protein. Lastly, a mixture of donor beads (anti-FLAG coated) and  
357 angiotensin-converting enzyme 2 (ACE2) protein (FLAG) were added to the reaction, by which  
358 non-neutralized spike-RBD protein would bind to the ACE2 receptor, bringing closer both  
359 acceptor and donor beads. Upon laser excitation, a photosensitizer present in the donor beads  
360 converted ambient oxygen to a more excited singlet state. The singlet oxygen channeled into the  
361 acceptor beads and reacted with a thioxene derivate in the acceptor beads, generating  
362 chemiluminescence at 370 nm that further activated a fluorophore (europium) embedded in the  
363 acceptor beads. The fluorophore subsequently emitted light at 615 nm, which was measured by  
364 the Envision reader. The amount of light generated in counts (cps) was inversely proportional to  
365 the amount of neutralizing antibodies against the RBD of the SARS-CoV-2 spike protein.

#### 366 **SARS-CoV-2 spike pseudotyped lentivirus assay**

367 Neutralizing antibody titers against the RBD of SARS-CoV-2 were also measured by quasi-  
368 quantification of the antibody response in a titer approach. This cell-based assay using 293T-  
369 hsACE2 cells is based on the principle that binding between the SARS-CoV-2 spike protein and  
370 the cellular receptor ACE2 protein is necessary for cellular infection. In the presence of  
371 neutralizing antibodies, the spike protein function is affected, and therefore, the binding between  
372 the spike and ACE2 proteins is negatively affected. This assay uses luciferase reporter virus  
373 particles (RVPs).

374 Samples were initially diluted in cell culture media and transferred to a 96-well plate. A known  
375 quantity of RVPs (or pseudovirus) was added and incubated to allow antibody binding. A set  
376 quantity of 293T-ACE2 cells was added, and plates were incubated for 48 hours. After the

377 incubation period, a luciferase substrate was added to each well, and relative light unit (RLU)  
378 values were read using luminescence settings. The amount of RLUs was inversely proportional  
379 to the amount of neutralizing antibodies against the SARS-CoV-2 spike protein.  
380 The inhibitory rates were calculated based on RLU values and used for assessing antibody and  
381 serum neutralization activities. The endpoint titers were calculated by serial dilutions of the  
382 samples.

### 383 **Cellular immunity assays**

#### 384 **FluoroSpot assay**

385 This FluoroSpot (FS) assay was conducted to detect and quantify interferon gamma (IFN- $\gamma$ ) and  
386 interleukin 4 (IL-4) secretion by antigen-stimulated human PBMCs. PBMCs were isolated from  
387 three groups, including participants of this trial, convalescent patients who were hospitalized and  
388 recovering from COVID-19, and participants of a separate study that enrolled individuals  
389 receiving the BNT162b2 mRNA vaccine. SARS-CoV-2 peptide pools (9-mers and 15-mers) and  
390 controls (Phytohemagglutinin, Dimethyl sulfoxide, and CPI [protein antigens of CMV,  
391 Parainfluenza and Influenza viruses]) were used as stimulants.  
392 Peptide pools used to stimulate PBMC are described in a previous paper<sup>27</sup>. In brief, the 15-mer  
393 peptide pool is a pool of 53 peptides derived from a peptide scan (15-mers with 11 amino acid  
394 overlap) through the RBD of SARS-CoV-2 (an original Wuhan strain) [JPT Peptides: PepMix  
395 SARS-CoV-2 (S-RBD) PM-WCPV-S-RBD-2]. The 9-mer peptide pool is a pool of 215 peptides  
396 derived from a peptide scan (9-mers with 8 amino acid overlaps) through the RBD of SARS-  
397 CoV-2 (an original Wuhan strain). The 9-mer peptide pool was custom-made by JPT Peptides. It  
398 is known that the 15-mer peptide pool induces both CD8<sup>+</sup> T cell response and CD4<sup>+</sup> T cell

399 response reliably, whereas the 9-mer peptide pool induces primarily CD8+ T cell response;  
400 however, the CD4+ T cell response is also induced less reliably<sup>31</sup>.  
401 FluoroSpot assay plates were washed with PBS and blocked with CTL media for  $\geq 30$  mins at  
402 37°C. Post-thaw PBMCs were seeded at  $4 \times 10^5$  cells per well (100  $\mu$ L) and stimulated in  
403 triplicate with one of the following five different stimulants: 1  $\mu$ g/mL of 9-mer SARS-CoV-2 or  
404 15-mer SARS-CoV-2 peptide pools, 5  $\mu$ g/mL CPI, 3  $\mu$ g/mL PHA, or DMSO (negative control).  
405 The final combined volume of cells and stimulant was 200  $\mu$ L per well. Following 48 hours of  
406 incubation, plates were washed and incubated with Fluorescein isothiocyanate (FITC)-labeled  
407 anti-IFN- $\gamma$  or biotinylated anti-IL-4 detection antibodies for 2 hours at room temperature in the  
408 dark. Plates were then washed and incubated for 1 hour at room temperature in the dark with  
409 either anti-FITC Alexa Fluor 488 tertiary antibody for detecting IFN- $\gamma$  or streptavidin CTL Red  
410 for detecting IL-4. Plates were finally washed with water and placed in the dark to dry overnight.  
411 Within 24-36 hours after development, plates were scanned using the CTL. The numbers of spot-  
412 forming cells (SFCs) were normalized to spots per million cells to yield spot-forming units  
413 (SFUs).

#### 414 **Safety assessment**

415 Local and systemic adverse events, as defined in the FDA guidance for preventive vaccine  
416 clinical trials, were solicited at each follow-up visit (Days 1, 8, 15, 29, 36, 43, 57, 92, 183, 365).  
417 Laboratory values including complete blood count, basic metabolic panel, liver function tests,  
418 and urinalysis were assessed on select follow-up visits (Days 1, 8, 29, 36, 57).

#### 419 **Statistical analysis**

420 Data were analyzed using R (version 4.1.0) and GraphPad Prism (version 10.0.2). Sample size  
421 was determined in advance primarily for feasibility considerations rather than through statistical

422 inferential testing. Due to a small sample size, only descriptive statistics were used and presented  
423 in this paper.

424

#### 425 **Supplementary materials**

426 The following supporting information can be downloaded at: [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1), Table S1:  
427 Antibody titers; Table S2: Antibody titers of external controls; Table S3: Neutralizing Antibody  
428 titers (Cell-free assays); Table S4: Neutralizing Antibody titers (Pseudovirus assays); Table S5:  
429 Fluorospot assay results at 1-year post-EXG-5003 vaccination; Table S6: Fluorospot assay  
430 results for external controls.

431

#### 432 **Author contributions**

433 TK, MT, HF, MaK, YD conducted the clinical trial at Fujita Health University. MiK coordinated  
434 regulatory activities. MSHK, TA, MA, MB, HY, PR, EL, JK, HY, ACK, NPW, AA were involved in  
435 EXG-5003 vaccine development. HY conducted data management. IT, ST, AS conducted planned  
436 statistical analyses. MSHK and YD conducted post-hoc statistical analyses and drafted the  
437 manuscript.

438

#### 439 **Funding**

440 This clinical trial was entirely supported by AMED under Grant Number JP21nf0101631. Elixirgen  
441 Therapeutics provided the EXG-5003 vaccine.

442

#### 443 **Institutional review board statement**

444 The protocol, amendments, and overall oversight were approved by the Central Institutional Review  
445 Board for the Fujita Health University Hospitals (F-D-18) (jRCT2041210013, NCT04863131). The  
446 study was conducted in accordance with the Declaration of Helsinki.

447

#### 448 **Informed consent statement**

449 Informed consent was obtained from all participants involved in the study.

450

#### 451 **Data availability statement**

452 The data presented in this study can be found in Figures, Tables, and Supplemental Tables.

453

#### 454 **Acknowledgments**

455 We thank Allie Amick, Ph.D. for editing the manuscript.

456

#### 457 **Conflicts of interest**

458 MiK is a paid consultant to Elixirgen Therapeutics, Inc. TA, HY, MA, MB, PR, ACK, MSHK are  
459 employees of Elixirgen Therapeutics, Inc. EL and JK were former employees of Elixirgen  
460 Therapeutics, Inc. AA and NW are employees of the National Institute on Aging, National Institutes  
461 of Health, and declare no competing interests. YD has served as a consultant for Moderna. TK, TM,  
462 TI, HY, ST, AS, HF, MaK declare no competing interest.

463

#### 464 **References**

- 465 1 WHO Coronavirus Dashboard (2023). <https://covid19.who.int/>
- 466 2 Excler, J. L. *et al.* Factors, enablers and challenges for COVID-19 vaccine development.  
467 *BMJ Glob Health* **8** (2023). <https://doi.org/10.1136/bmjgh-2023-011879>

- 468 3 Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N*  
469 *Engl J Med* **384**, 403-416 (2021). <https://doi.org/10.1056/NEJMoa2035389>
- 470 4 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N*  
471 *Engl J Med* **383**, 2603-2615 (2020). <https://doi.org/10.1056/NEJMoa2034577>
- 472 5 Moss, P. The T cell immune response against SARS-CoV-2. *Nat Immunol* **23**, 186-193  
473 (2022). <https://doi.org/10.1038/s41590-021-01122-w>
- 474 6 Sette, A., Sidney, J. & Crotty, S. T Cell Responses to SARS-CoV-2. *Annu Rev Immunol*  
475 **41**, 343-373 (2023). <https://doi.org/10.1146/annurev-immunol-101721-061120>
- 476 7 Wherry, E. J. & Barouch, D. H. T cell immunity to COVID-19 vaccines. *Science* **377**,  
477 821-822 (2022). <https://doi.org/10.1126/science.add2897>
- 478 8 Anderson, E. J. *et al.* Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine  
479 in Older Adults. *N Engl J Med* **383**, 2427-2438 (2020).  
480 <https://doi.org/10.1056/NEJMoa2028436>
- 481 9 Nathan, A. *et al.* Structure-guided T cell vaccine design for SARS-CoV-2 variants and  
482 sarbecoviruses. *Cell* **184**, 4401-4413 e4410 (2021).  
483 <https://doi.org/10.1016/j.cell.2021.06.029>
- 484 10 Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N*  
485 *Engl J Med* **383**, 1920-1931 (2020). <https://doi.org/10.1056/NEJMoa2022483>
- 486 11 Munro, A. P. S. *et al.* Safety, immunogenicity, and reactogenicity of BNT162b2 and  
487 mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of  
488 ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a  
489 multicentre, blinded, phase 2, randomised trial. *Lancet Infect Dis* **22**, 1131-1141 (2022).  
490 [https://doi.org/10.1016/S1473-3099\(22\)00271-7](https://doi.org/10.1016/S1473-3099(22)00271-7)

- 491 12 Ozbay Kurt, F. G. *et al.* Booster dose of mRNA vaccine augments waning T cell and  
492 antibody responses against SARS-CoV-2. *Front Immunol* **13**, 1012526 (2022).  
493 <https://doi.org/10.3389/fimmu.2022.1012526>
- 494 13 Hernandez, S. P. A. *et al.* Three doses of BNT162b2 COVID-19 mRNA vaccine establish  
495 long-lasting CD8(+) T cell immunity in CLL and MDS patients. *Front Immunol* **13**,  
496 1035344 (2022). <https://doi.org/10.3389/fimmu.2022.1035344>
- 497 14 Reinscheid, M. *et al.* COVID-19 mRNA booster vaccine induces transient CD8+ T  
498 effector cell responses while conserving the memory pool for subsequent reactivation.  
499 *Nat Commun* **13**, 4631 (2022). <https://doi.org/10.1038/s41467-022-32324-x>
- 500 15 Agrati, C. *et al.* Persistent Spike-specific T cell immunity despite antibody reduction after  
501 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. *Sci Rep* **12**, 6687 (2022).  
502 <https://doi.org/10.1038/s41598-022-07741-z>
- 503 16 Blakney, A. K., Ip, S. & Geall, A. J. An Update on Self-Amplifying mRNA Vaccine  
504 Development. *Vaccines (Basel)* **9** (2021). <https://doi.org/10.3390/vaccines9020097>
- 505 17 McKay, P. F. *et al.* Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine  
506 candidate induces high neutralizing antibody titers in mice. *Nat Commun* **11**, 3523  
507 (2020). <https://doi.org/10.1038/s41467-020-17409-9>
- 508 18 de Alwis, R. *et al.* A single dose of self-transcribing and replicating RNA-based SARS-  
509 CoV-2 vaccine produces protective adaptive immunity in mice. *Mol Ther* **29**, 1970-1983  
510 (2021). <https://doi.org/10.1016/j.ymthe.2021.04.001>
- 511 19 Erasmus, J. H. *et al.* An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2  
512 neutralizing antibody and T cell responses in mice and nonhuman primates. *Sci Transl*  
513 *Med* **12** (2020). <https://doi.org/10.1126/scitranslmed.abc9396>

- 514 20 Langereis, M. A. *et al.* An alphavirus replicon-based vaccine expressing a stabilized  
515 Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2  
516 between cats. *NPJ Vaccines* **6**, 122 (2021). <https://doi.org/10.1038/s41541-021-00390-9>
- 517 21 Szurgot, I. *et al.* DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2  
518 immune responses in mice. *Sci Rep* **11**, 3125 (2021). [https://doi.org/10.1038/s41598-021-](https://doi.org/10.1038/s41598-021-82498-5)  
519 [82498-5](https://doi.org/10.1038/s41598-021-82498-5)
- 520 22 Rappaport, A. R. *et al.* Low-dose self-amplifying mRNA COVID-19 vaccine drives  
521 strong protective immunity in non-human primates against SARS-CoV-2 infection. *Nat*  
522 *Commun* **13**, 3289 (2022). <https://doi.org/10.1038/s41467-022-31005-z>
- 523 23 Komori, M. *et al.* saRNA vaccine expressing membrane-anchored RBD elicits broad and  
524 durable immunity against SARS-CoV-2 variants of concern. *Nat Commun* **14**, 2810  
525 (2023). <https://doi.org/10.1038/s41467-023-38457-x>
- 526 24 Akahata, W. *et al.* Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA  
527 vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study. *Cell*  
528 *Rep Med* **4**, 101134 (2023). <https://doi.org/10.1016/j.xcrm.2023.101134>
- 529 25 Elliott, T. *et al.* Enhanced immune responses following heterologous vaccination with  
530 self-amplifying RNA and mRNA COVID-19 vaccines. *PLoS Pathog* **18**, e1010885  
531 (2022). <https://doi.org/10.1371/journal.ppat.1010885>
- 532 26 Low, J. G. *et al.* A phase I/II randomized, double-blinded, placebo-controlled trial of a  
533 self-amplifying Covid-19 mRNA vaccine. *NPJ Vaccines* **7**, 161 (2022).  
534 <https://doi.org/10.1038/s41541-022-00590-x>



- 535 27 Amano, T. *et al.* Controllable self-replicating RNA vaccine delivered intradermally  
536 elicits predominantly cellular immunity. *iScience* **26**, 106335 (2023).  
537 <https://doi.org/10.1016/j.isci.2023.106335>
- 538 28 Dugan, H. L., Henry, C. & Wilson, P. C. Aging and influenza vaccine-induced immunity.  
539 *Cell Immunol* **348**, 103998 (2020). <https://doi.org/10.1016/j.cellimm.2019.103998>
- 540 29 Hickling, J. K. *et al.* Intradermal delivery of vaccines: potential benefits and current  
541 challenges. *Bull World Health Organ* **89**, 221-226 (2011).  
542 <https://doi.org/10.2471/BLT.10.079426>
- 543 30 Pollock, K. M. *et al.* Safety and immunogenicity of a self-amplifying RNA vaccine  
544 against COVID-19: COVAC1, a phase I, dose-ranging trial. *EClinicalMedicine* **44**,  
545 101262 (2022). <https://doi.org/10.1016/j.eclinm.2021.101262>
- 546 31 Kiecker, F. *et al.* Analysis of antigen-specific T-cell responses with synthetic peptides--  
547 what kind of peptide for which purpose? *Hum Immunol* **65**, 523-536 (2004).  
548 <https://doi.org/10.1016/j.humimm.2004.02.017>
- 549  
550

551 **Table 1. Participants demographics.**  
552

|                          | Cohort 1                |                  | Cohort 2                 |                  |
|--------------------------|-------------------------|------------------|--------------------------|------------------|
|                          | EXG-5003 5 µg<br>(n=16) | Placebo<br>(n=4) | EXG-5003 25 µg<br>(n=16) | Placebo<br>(n=4) |
| Race                     |                         |                  |                          |                  |
| Asian                    | 16 (100%)               | 4 (100%)         | 16 (100%)                | 4 (100%)         |
| Gender                   |                         |                  |                          |                  |
| Male                     | 10 (62.5%)              | 3 (75%)          | 7 (43.8%)                | 4 (100%)         |
| Female                   | 6 (37.5%)               | 1 (25%)          | 9 (56.2%)                | 0 (0%)           |
| Age (year)               |                         |                  |                          |                  |
| Mean                     | 39.375                  | 46.75            | 39.562                   | 42.75            |
| SD                       | 8.405                   | 7.932            | 10.354                   | 4.272            |
| Median                   | 39.5                    | 48.0             | 43.0                     | 44.0             |
| Min-Max                  | 22 - 53                 | 36 - 55          | 22 - 55                  | 37 - 46          |
| Weight (kg)              |                         |                  |                          |                  |
| Mean                     | 66.862                  | 64.8             | 63.094                   | 74.625           |
| SD                       | 18.756                  | 4.721            | 12.837                   | 10.633           |
| Median                   | 61.5                    | 65.85            | 63.05                    | 72.9             |
| Min-Max                  | 46.9 - 107.8            | 58.2 - 69.3      | 47.5 - 84.7              | 65 - 87.7        |
| Height (cm)              |                         |                  |                          |                  |
| Mean                     | 169.200                 | 169.375          | 164.162                  | 169.175          |
| SD                       | 8.791                   | 6.874            | 8.804                    | 5.142            |
| Median                   | 170.550                 | 172.55           | 164.550                  | 170.35           |
| Min-Max                  | 154.2 - 183.1           | 159.1 - 173.3    | 152 - 180                | 162 - 174        |
| BMI (kg/m <sup>2</sup> ) |                         |                  |                          |                  |
| Mean                     | 23.265                  | 22.575           | 23.301                   | 26.173           |
| SD                       | 6.072                   | 0.534            | 3.680                    | 4.374            |
| Median                   | 21.484                  | 22.593           | 22.637                   | 26.269           |
| Min-Max                  | 17.849 - 39.789         | 22.039 - 23.075  | 16.553 - 29.938          | 22.13 - 30.026   |

553 Note. SD, standard deviation; Min, minimum; Max, maximum; BMI, body mass index.

554 **FIGURE LEGENDS**

555

556 **Figure 1.** A flow chart showing enrollment and randomization of participants. Cohort 1 (5 µg  
557 group) was dosed first. After the second dose, the safety was monitored for two weeks. Then,  
558 Cohort 2 (25 µg group) was dosed.

559

560 **Figure 2.** Safety of EXG-5003. (A) Frequency of local adverse events within 7 days of  
561 vaccination and a photo example of redness at the intradermal injection site. (B) Frequency of  
562 systemic adverse events within 7 days of vaccination.

563

564 **Figure 3.** Humoral immune responses against the RBD of SARS-CoV-2. Geometric means of  
565 antibody titers. (A) Geometric means of anti-RBD antibody titer. (B) Geometric means of  
566 neutralization antibody titer by cell-free SARS-CoV-2 neutralization assay. (C) Geometric  
567 means of neutralization antibody titer by the SARS-CoV-2 spike pseudo-typed lentivirus assay.  
568 Red color indicates participants who received at least one dose of approved mRNA vaccine  
569 (BNT162b2 or mRNA-1273). FAS, the full analysis data set.

570

571 **Figure 4.** Cellular immune responses against the RBD of SARS-CoV-2. (A) IFN-γ spot-forming  
572 units (SFU) per 10<sup>6</sup> PBMCs stimulated by 15-mer RBD peptide library. (B) IFN-γ SFU per  
573 10<sup>6</sup> PBMCs stimulated by 9-mer RBD peptide library. (C) IL-4 SFU per 10<sup>6</sup> PBMCs  
574 stimulated by 15-mer RBD peptide library. (D) IL-4 SFU per 10<sup>6</sup> PBMCs stimulated by 9-mer  
575 RBD peptide library. Red color indicates data points after receiving at least one dose of approved  
576 mRNA vaccine (BNT162b2 or mRNA-1273). External controls (for 15-mer RBD peptide

577 library): Convalescent (n=3, blood was collected 20, 21, 22 days after the onset of symptoms,  
578 respectively), BNT162b2 vaccine (pre) (n=4, before receiving 1st dose of BNT162b2),  
579 BNT162b2 (1 dose) (n=3, two weeks after receiving the 1st dose of BNT162b2), BNT162b2  
580 vaccine (2 doses) (n=3, two weeks after receiving the 2nd dose of BNT162b2). External controls  
581 (for 9-mer RBD peptide library): Convalescent (n=1, blood was collected 20 days after the onset  
582 of symptoms, respectively), BNT162b2 vaccine (pre) (n=1, before receiving 1st dose of  
583 BNT162b2), BNT162b2 vaccine (2 doses) (n=1, two weeks after receiving the 2nd dose of  
584 BNT162b2).

585  
586 **Figure 5.** Cohort 2 cellular immune response data replotted from Figure 4 by log-scale. IFN- $\gamma$   
587 spot-forming units (SFU) per  $10^6$  PBMCs stimulated by 15-mer peptide library. Placebo (n=4)  
588 in blue dots (left). EXG-5003 (25  $\mu$ g, n=16) in red dots (middle). External controls:  
589 Convalescent (n=3, blood was collected 20, 21, 22 days after the onset of symptoms,  
590 respectively), BNT162b2 vaccine (pre) (n=4, before receiving 1st dose of BNT162b2),  
591 BNT162b2 vaccine (dose 1) (n=3, two weeks after receiving the 1st dose of BNT162b2),  
592 BNT162b2 vaccine (2 doses) (n=3, two weeks after receiving the 2nd dose of BNT162b2).  
593 External controls (for 9mer peptide library): Convalescent (n=1, blood was collected 20 days  
594 after the onset of symptoms, respectively), BNT162b2 vaccine (pre) (n=1, before receiving 1st  
595 dose of BNT162b2), BNT162b2 vaccine (2 doses) (n=1, two weeks after receiving the 2nd dose  
596 of BNT162b2).

597  
598 **Figure 6.** Long-term humoral immunity assessed by serum collected at 3 months, 6 months, and  
599 1-year post-dosing with placebo (PBO), EXG-5003 (5  $\mu$ g), or EXG-5003 (25  $\mu$ g). Participants

600 who received the approved mRNA vaccines (BNT162b2 or mRNA-1273) more than 10 days  
601 before the serum collection are shown. (A) Anti-RBD antibody titer. (B) Neutralization antibody  
602 titer by cell-free SARS-CoV-2 neutralization assay. (C) Neutralization antibody titer by the  
603 SARS-CoV-2 spike pseudo-typed lentivirus assay. \* indicates individuals who became positive  
604 for antibodies against SARS-CoV-2 nucleoprotein, i.e., infected during 1-year follow-up period.

605

606 **Figure 7.** Long-term cellular immunity assessed by PBMCs collected at 1-year post-dosing with  
607 placebo (PBO), EXG-5003 (5 µg), or EXG-5003 (25 µg).

608 (A) IFN-γ spot-forming units (SFU) per 10<sup>6</sup> PBMCs stimulated by 15-mer RBD peptide  
609 library. Participants were subdivided into three groups based on the timing of receiving the  
610 approved mRNA vaccines (BNT162b2 or mRNA-1273): No booster (days after receiving PBO  
611 [337 days], EXG-5003 5 µg [337 days], or EXG-5003 25 µg [337 days]), 2x booster (days after  
612 receiving the 2<sup>nd</sup> dose of approved vaccines: PBO [205, 262 days], EXG-5003 5 µg [70, 190,  
613 212, 253 days]; EXG-5003 25 µg [3, 205, 253, 270, 272, 283 days]), 3x booster (days after  
614 receiving the 3<sup>rd</sup> dose of approved vaccines: PBO [46, 59, 63, 78 days]; EXG-5003 5 µg [13, 20,  
615 21, 40 days]; EXG-5003 25 µg [20, 26, 61, 63, 68 days]). External controls (reproduced from  
616 Figure 5 for comparison): Convalescent (n=3, blood was collected 20, 21, 22 days after the onset  
617 of symptoms, respectively), BNT162b2 (pre) (n=4, before receiving 1st dose of BNT162b2),  
618 BNT162b2 (1 dose) (n=3, two weeks after receiving the 1st dose of BNT162b2), BNT162b2 (2  
619 doses) (n=3, two weeks after receiving the 2nd dose of BNT162b2). \* indicates individuals who  
620 became positive for antibodies against SARS-CoV-2 nucleoprotein, i.e., infected during 1-year  
621 follow-up period.

622

623 (B) IFN- $\gamma$  SFU per  $10^6$  PBMCs stimulated by 9-mer RBD peptide library. Participants were  
624 subdivided into three groups based on the timing of receiving the approved mRNA vaccines  
625 (BNT162b2 or mRNA-1273): No booster (days after receiving EXG-5003 5  $\mu$ g [337 days], or  
626 EXG-5003 25  $\mu$ g [337 days]), 2x booster (days after receiving the 2<sup>nd</sup> dose of approved vaccines:  
627 PBO [205, 262 days], EXG-5003 5  $\mu$ g [70, 190, 212, 253 days]; EXG-5003 25  $\mu$ g [3, 205, 270  
628 days]), 3x booster (days after receiving the 3<sup>rd</sup> dose of approved vaccines: PBO [78 days]; EXG-  
629 5003 5  $\mu$ g [13, 21, 40 days]; EXG-5003 25  $\mu$ g [20, 25, 63 days]). External controls (for 9mer  
630 peptide library): Convalescent (n=1, blood was collected 20 days after the onset of symptoms,  
631 respectively), BNT162b2 (pre) (n=1, before receiving 1st dose of BNT162b2), BNT162b2 (2  
632 doses) (n=1, two weeks after receiving the 2nd dose of BNT162b2). \* indicates individuals who  
633 became positive for antibodies against SARS-CoV-2 nucleoprotein, i.e., infected during 1-year  
634 follow-up period.  
635





Figure 1



**Figure 2**







Figure 3



**Figure 4**






Figure 5



**Figure 6**



**Figure 7**